Infliximab bills in 10 mg units. A 400 mg dose is 40 units on the claim. Enter 400, and the claim either denies for exceeding the payer’s unit limit or, worse, pays and gets recouped later. Drugs like this cost thousands of dollars per dose, so a unit error turns a routine claim into a five-figure problem.
Most specialty drug revenue is lost in the details around the drug, not the drug code itself. That means units, NDCs, waste modifiers, which benefit covers the drug, and whether the authorization matches what was given.
Key Takeaways
- Billed units come from the HCPCS code’s dosage descriptor, not the milligrams given or the number of vials.
- Most payers require the 11-digit NDC, quantity, and unit of measure on drug claims alongside the HCPCS code.
- Medicare requires the JW modifier for discarded drug from single-dose containers and JZ when none was discarded.
- Medicare Part B doesn’t cover drugs on its self-administered drug list, so drugs patients usually inject at home fall to the pharmacy benefit.
- Most biologics need prior authorization, and many need reauthorization every 6 to 12 months.
HCPCS Codes, Units, and NDCs
Physician-administered biologics bill under HCPCS Level II codes, mostly J-codes, with Q-codes for some newer products and cell therapies. Each code has a dosage descriptor, and the units on the claim are the dose given divided by that descriptor. Trastuzumab (J9355) bills per 10 mg, bortezomib (J9041) per 0.1 mg, and infliximab (J1745) per 10 mg. A drug with no specific code bills under an unclassified code such as J3490 or J9999, with the drug name, NDC, and dose in the claim notes.
Most payers also require the National Drug Code in 11-digit format, with the N4 qualifier, the quantity, and the unit of measure such as UN, ML, or GR. The NDC quantity and the HCPCS units measure different things, and payers check that they’re consistent with each other and with the NDC billed. Biosimilars have their own HCPCS codes, often with a Q-code and a product-specific modifier, so the code has to match the exact product given. Our guide to which codes are used in biologics and specialty drugs billing lists more examples.
Administration Codes
The drug and its administration bill separately. Most biologics given by IV infusion bill as 96365 for the first hour and 96366 for each additional hour. Many monoclonal antibodies and other complex biologics qualify for the chemotherapy and complex drug administration codes, 96413 and 96415, when the drug requires that level of monitoring, even for non-cancer diagnoses. Subcutaneous or intramuscular injections bill as 96372, or 96401 for hormonal and anti-neoplastic injections. The infusion start and stop times have to be documented to support the hours billed. Our oncology page covers chemotherapy administration in more detail.
Medicare Rules for Part B Drugs
Medicare pays most Part B drugs at the average sales price plus 6 percent, with qualifying biosimilars paid at a higher add-on for a limited time. Drugs from single-dose vials need the JW modifier on a separate line for any amount discarded, or the JZ modifier when nothing was discarded. Missing both is a claim error.
Hospital outpatient departments and other covered entities that buy drugs through the 340B program must report the TB modifier on Medicare Part B drug claims for those drugs. The modifier doesn’t change payment for most providers but is required for tracking.
Medicare Part B doesn’t cover drugs that are usually self-administered. Each Medicare contractor publishes a self-administered drug exclusion list, and drugs such as adalimumab, which patients inject at home, fall under Part D instead. Billing one of those drugs as an in-office injection to Part B will deny.
Medical Benefit vs. Pharmacy Benefit
Commercial plans may cover the same biologic under the medical benefit when the practice buys it and bills it, or under the pharmacy benefit when a specialty pharmacy ships it. Some plans require white bagging, where the specialty pharmacy ships the drug to the practice for administration, and the practice bills only the administration. Billing the drug when it was supplied by a specialty pharmacy is a duplicate claim.
Before the first dose, the practice needs to know which benefit covers the drug, whether buy-and-bill is allowed, and who holds the authorization. Many plans also run site-of-care programs that require infusions to move from a hospital outpatient department to an office, ambulatory infusion center, or the patient’s home. Practices that send patients home for infusion follow the rules on our home infusion therapy page.
Prior Authorization and Reauthorization
Nearly every biologic needs prior authorization. Approval usually depends on the diagnosis, lab values, and documented failure of conventional therapy, and many plans require trying a preferred biosimilar first. Authorizations set the drug, dose, frequency, and a date range, often 6 to 12 months, so a dose change or a switch to a biosimilar needs a new approval. When the authorized product or dose doesn’t match the claim, it can deny even though the patient was approved, which we cover in why an approved authorization can still end in a denied claim.
Manufacturer copay programs and foundations can cover much of a commercially insured patient’s cost share, but they can’t be used for Medicare or Medicaid patients. Enrolling eligible patients before the first infusion keeps balances from building up.
Credentialing for Infusion Practices
Practices that administer biologics, including rheumatology, gastroenterology, oncology, neurology, and dermatology, need each prescribing physician and NPP enrolled with every plan they bill. Ambulatory infusion centers often need their own enrollment and contracts, separate from the physicians who order the infusions, and some payers only route site-of-care patients to infusion centers in their network. Until each provider and site is approved, infusions there can’t be billed, which is why you can’t bill what you can’t credential.
Biologics Billing FAQs
How are units calculated for a biologic drug claim?
Divide the dose given by the HCPCS code’s dosage descriptor. A 400 mg dose of infliximab, billed per 10 mg under J1745, is 40 units.
When are the JW and JZ modifiers required?
Medicare requires JW for the discarded amount of a drug from a single-dose container, billed on a separate line, and JZ when no drug was discarded.
Does Medicare Part B cover Humira?
No. Adalimumab is usually self-administered, so it’s on the Medicare contractors’ self-administered drug exclusion lists and falls under Part D.
Do biologic claims need an NDC?
Most payers require the 11-digit NDC with the N4 qualifier, quantity, and unit of measure in addition to the HCPCS code.
What is white bagging?
It’s when a specialty pharmacy ships the drug to the practice for a specific patient. The practice bills only the administration, not the drug.
Can manufacturer copay cards be used for Medicare patients?
No. Manufacturer copay programs can’t be used for patients with Medicare or Medicaid. Independent foundations may help some of those patients.
Medwave’s Specialty Drug Billing Team
One biologic claim can be worth more than a month of office visits, so small mistakes cost real money. Medwave confirms the authorization before each dose, checks billed units against the HCPCS descriptor and the NDC, and puts JW or JZ on every single-dose vial. Specialty drug claims through our billing team clear at 98%.
Our credentialing team enrolls the physicians and APPs who order and give these drugs, which takes about 85 days. Our payer contracting reviews compare each plan’s drug payment against ASP and your acquisition cost, so you can see which plans pay less than the drug costs you.
Buy-and-bill practices can send us their payer mix below.